Introduction
Environmental mutagens can produce disease in individuals by "inducing" lesions in critical genes of somatic cells. If the genes are important in malignant transformation, the disease is cancer. Other diseases may also have an environmental basis. Measures of induced or spontaneous genetic damage arising in vivo in human somatic cells have public health relevance as early warning detectors for such exposures. Environmentally induced lesions in cells may be manifest at any level of organization of the genetic material, i.e., the chromosome, the gene, or the primary DNA level. Assays are available for quantifying and characterizing all such damage. At the chromosome level, technical advances in recent years have increased the rapidity and precision of measures of aberrations and micronuclei. For primary DNA lesions, there is a variety of methods for measuring chemical adducts, other lesions, or cellular repair responses that reflect such lesions (1) .
Genetic lesions in somatic cells are processed, resulting in misinformation (or no information) encoded by the involved region of DNA. Broadly speaking, such processed lesions are called "mutations." Chromosome-level genetic damage may result in a mutation if it is not lethal to the cell and disrupts or deletes a gene or its controlling elements. Similarly, primary DNA lesions, while not themselves mutations, may be processed to produce changes in somatic genetic coding sequences. The final common pathway for somatic genetic damage to be of functional (i.e., pathogenic) significance is a heritable alteration in genetic information, i.e., a somatic gene mutation. Measures of somatic mutations are relevant for human population monitoring because they measure this common functional pathway. When these mutations occur in critical regions, they produce genotoxic disease.
Most studies of human genotoxic diseases are concerned with genes involved in the disorder. Cancer research has become highly focused on the critical genes involved in malignant transformation. Certainly, studies of specific oncogenes and tumor-suppressor genes are indis-pensable for an understanding of pathogenesis, i.e., for relating gene malfunctions to disease states. However, genetic lesions arising in cancer-associated genes are rare, usually nonselectable, and, when they do arise, may alter cell proliferation characteristics such that their primary frequencies become difficult to measure. For investigations of the mutation process itself and for monitoring human exposures to environmental mutagens, recourse is made to somatic mutations in simple "housekeeping" or other genes that result in easily recognized cellular phenotypic changes. Such somatic mutations serve as recorders. Of course, ultimately, correlations must be made between mutations in recorder genes and genotoxic diseases in monitored populations for the former to have validity for human risk assessment.
This review briefly considers and compares all currently available assays for measuring in vivo somatic cell gene mutations in humans. Special emphasis is given to hypoxanthine-guanine phosphoribosyltransferase (hprt) mutations in T-lymphocytes for three reasons: it is used by several laboratories, it has the largest current database, and information is available regarding molecular characterizations of the mutations arising in vivo.
Assays for Somatic Cell Mutations Arising in Vivo in Humans
There currently are four assays for detecting in vivo somatic cell gene mutations in humans. All measure altered cellular phenotypes. For obvious reasons, the current assays study mutations in blood cells; two in red blood cells (RBCs) and two in T-lymphocytes.
Somatic Mutations in Red Blood Cells
Somatic mutations of the hemoglobin (Hb) genes and the glycophorin-A (gpa) gene are reflected as altered phenotypes in RBCs. Although the concept of monitoring in vivo somatic mutations by studying changes in Hb came first, an automated assay for actually scoring mutants was only recently developed (2, 3) . By far, most studies of in vivo mutations detected as RBC changes have used the GPA assay.
Since mature RBCs in mammals do not have a nucleus, the mutations that produce phenotypic alterations must arise at an earlier stage of differentiation, i.e., in nucleated bone marrow progenitor cells. Genotoxicants must reach this body compartment to exert their effects. Bone marrow derived mutants are then amplified and recognized as RBCs in peripheral blood. This relationship between mutational events and mutant frequencies must be understood to interpret mutagenicity studies using this assay. At least some of the mutations induced in bone marrow precursor cells will arise in multipotent stem cells that produce cells that begin the differentiation process and cells that renew the stem-cell compartment. Because of the latter, mutations occurring in multipotent cells are reflected as mutants throughout the life of the individual, i.e., have "long memory." (Those arising in more differentiated cells will eventually die out.) This long memory may or may not be an advantage, depending on whether monitoring is for genotoxic exposures in the recent or distant past.
A further consequence of RBCs not having a nucleus is that there is no possibility for molecular studies. Therefore, indirect methods must be used to verify the mutational basis of the phenotypic changes and molecular mutational spectra cannot be determined. RBCs (6) .
Glycophorin A is the cell surface protein on RBCs that defines the M and N blood group antigens. The M and N groups differ by two nonadjacent amino acids, are codominantly expressed on RBCs, and are specified by the only two alleles at the gpa locus (7). The gpa mutants are recognized on rare RBCs of an M/N constitutional heterozygote as either the simple loss of M or N expression or loss of expression of one (M or N), with double expression of the other. Although the system has the disadvantage that only M/N heterozygous individuals are informative, the M and N gene frequencies are approximately equal in all populations so that heterozygotes are approximately 50% of all individuals. The simple loss of M or N expression (called "hemizygous" mutation) is thought to arise from allele inactivation somatic mutation (e.g., point mutation or deletion), whereas loss of one with double expression of the other (called "homozygous" mutation -not be confused with constitutional homozygote) is believed to represent somatic recombination, gene conversion, or chromosome loss with duplication. The gpa locus is on chromosome 4q, spans 44 kb and has 4 exons (8). It is a large target for mutation, as reflected in background mutant frequencies in normal adults, which are of the order of 10-20 x 10-6 for both hemizygous and homozygous mutants. These gpa mutants (variants) are enumerated by the use of a flow cytometer with RBCs that have been treated with highly specific anti-M and anti-N antibodies linked to green and red fluorophors, respectively (9, 10) .
The RBC assays have several advantages for human population monitoring. Because RBCs are so abundant in blood, relatively small samples suffice for analysis. The Hb assay measures precise gene alterations, making it virtually impossible for nongenetic phenotypic changes ("phenocopies") to produce the variant cells scored as mutants. However, the precise nature of these requisite mutations is a difficulty, i.e., mutant frequencies are so low that large numbers of cells must be scored to achieve statistical reliability, and some types of genetic change will not be detected. The former problem may be partially overcome by mixing several antimutant Hb antibodies when treating fixed cells, thereby measuring several different HboI mutations simultaneously. The use of an image analyzer greatly enhances the utility of this assay. The GPA assay has several advantages for human monitoring. It is extremely rapid, allowing for large numbers of individuals to be easily studied. Also, it allows for recognition of potentially important genetic lesions such as somatic recombination because of the autosomal location and large target characteristics of the gene.
Somatic Mutations in T-Lymphocytes
Somatic mutations arising in vivo in the hprt gene or in one or more of the HLA genes can be recognized in human T-lymphocytes. A short-term assay for quantitating the former was described almost 15 years ago, and a cloning assay for hprt mutations became available almost 10 years ago (11) (12) (13) . Several groups now use one or the other of these assays for human studies (14, 15) . A cloning assay for studying HLA mutations arising in vivo in T-lymphocytes was described almost 5 years ago (16) .
One advantage of T-lymphocytes for in vivo mutagenicity studies is that, when the cloning assay is used, in vivo-derived mutants can be isolated, propagated in vitro, and the mutation characterized at the molecular level. A large database containing such information is developing for hprt mutations where the background molecular mutational spectrum in nonmutagenic individuals is being characterized for comparison with spectra observed after various environmental exposures (17) . The hope is that mutagens or classes of mutagens will produce sufficiently characteristic spectra of hprt damage to serve as signatures for that specific exposure. If this hope is realized, qualitative studies of in vivo somatic mutations may be more informative than quantitative studies.
The T-lymphocyte population in vivo has enormous heterogeneity. At the extreme, this population consists of millions of individual in vivo clones, each identified by the specific T-cell receptor (TcR) used by all members of that clone. Specific T-cell receptors are dimeric cell-surface proteins through which individual T-cells recognize foreign antigen. Specific T-cell receptors are specified by TcR genes that themselves undergo somatic diversiflcation by a process ofrearrangement of segments of germ-line genes. The TcR rearrangement pattern of a given clone, fixed during thymic differentiation, persists throughout the life of the individual. Each of the millions of individual TcRdefined T-cell clones is thereby characterized by a specific and identifiable rearrangement of TcR genes. This can be used to advantage in that molecular analyses of TcR genes in T-cell mutants (selected on the basis of their mutation of some other gene, e.g., hprt or HLA) defines the randomness of the somatic mutation process or, conversely, its clonality, i.e., tendency to occur in a nonrandom manner among clones. Thus, the clonal distribution of somatic mutation can be established (18) .
As for RBCs, the in vivo kinetics of T-cells make interpretating mutation studies complex. T-lymphocytes arise in the bone marrow, undergo maturation (rearrangement of TcR genes) in the thymus, and then have a prolonged life span in peripheral tissue, e.g., in lymph nodes, spleen, gut. They travel from site to site via the blood. This traffic from bone marrow to thymus to periphery is pronounced during fetal life and early childhood, becomes less pronounced with age, and may terminate in late adolescence. There are few or no stem cells as such in the adult; the long-lived T-cells in the periphery maintain the T-lymphocyte population, and there is no further addition to clonal diversity. Most T-cells in the periphery at any given time are quiescent, i.e., in the Go phase of the cell cycle, but are intermittently stimulated to undergo cell division and clonal amplification, usually by antigen.
Somatic mutations in T-lymphocytes may occur at several differentiation stages in the fetus and children, but probably can arise only in the periphery (i.e., in mature T-cells) in adults. Because peripheral T-cells are present in virtually all body compartments, mutagens can exert their effects on these cells without having to reach the bone marrow compartment. Mutations arising in the periphery, however, do not have long memory, and T-cell mutations in adults will probably produce transient increases in in vivo mutant frequencies. This is advantageous or disadvantageous, depending on the purpose of the study.
The hprt gene is on the X-chromosome (19) . Thus, it is hemizygous, either actually (males) or functionally (females). The hprt gene is a constitutive but dispensable housekeeping gene that codes for an enzyme (HPRT) that phosphoribosylates hypoxanthine and guanine for purine salvage. HPRT activity is also able to phosphoribosylate purine analogues, e.g., 6-thioguanine (TG), to render them cytotoxic. Inactivating mutations of the hprt gene allow the mutant cells to grow in the presence of otherwise toxic concentrations ofpurine analogues, providing a convenient means for selection. The X-chromosomal location of the hprt gene is advantageous in obviating dominancerecessive considerations, but disadvantageous in that important genotoxic events such as somatic recombination cannot be detec-ted. The hprt gene spans 44 kb and includes nine exons, making it a large target for mutation as reflected in background adult mutant frequency values that average 5-10 x 10-6 (20) .
Two classes of assays are available for quantitating in vivo hprt mutations. One involves a short-term assay using autoradiography or immunofluorescence to detect 3H [thymidine] or bromodeoxyuridine (BrdU) incorporation, respectively, in mutant (variant) cells that are resistant to TG inhibition of first-round phytohemagglutinin (PHA)-stimulated DNA synthesis in vitro (11, 21) . These short term assays are simple, relatively inexpensive, and have the potential for automation.
The second assay for hprt mutant T-cells uses direct cloning. T-cells are cultured in limiting dilutions in the presence and absence of TG selection (12, 13 variety of inactivating mutations giving hemizygous variants and events akin to somatic mutation giving homozygous variants (22) . The background mean frequency of each of these is approximately 10 x 10-6, i.e., more than two orders of magnitude greater that for Hb variants. Mean hprt variant (short-term assay) and hprt mutant (cloning assay) frequencies have been established for normal nonmutagen-exposed adults. These are approximately the same, i.e., 5-10 x 10-6, as might be expected since they each measure in vivo mutation of the same gene, which is large target (17, 21, (23) (24) (25) . Some genetic events however (e.g., somatic recombination), are not detectable at hprt. Finally, the mean background mutant frequency at HLA is approximately 30 x 10-6, which reflects the large target size and the ability to record somatic exchanges (16, 26) . The relative order of mean background variant/ mutant frequencies for normal adults is Hb < hprt < gpa < HLA.
Superimposed on these mean background frequencies may be age effects and smoking effects. Although, strictly speaking, smoking is a mutagen exposure, it is so ubiquitous that it must be accounted for in human population monitoring. An increase in variant/mutant frequency with age has been found for all assays tested (9, (25) (26) (27) (28) (29) (30) (31) . Smoking has been found to increase mean gpa variant and hprt variant and mutant frequency values (25, 28, (31) (32) (33) . The magnitude of increase, however, varied from study to study and did not always reach statistical significance. There is no report of this having been tested for HLA mutations, and there was no smoking related increase in a small study of Hb somatic mutations.
Studies of in vivo somatic mutations in individuals with DNA deficiencies have been particularly interesting. Both gpa variant and hprt mutant frequencies are increased in patients with ataxia telangiectasia [AT (34, 35) ]. The increase for gpa is primarily for hemizygous variants. There was no increase in Hb variant frequencies in AT patients (31) . For xeroderma pigmentosum (XP), there was no increase in variant frequency for either Hb or gpa, but a clear increase in mutant frequency for hprt (22, 31, 36) . It is tempting to think that this reflects the necessity of the mutagen reaching the bone marrow compartments for the production of RBC precursor mutations, and the ability of lymphocytes to circulate through skin and be subject to UV effects. HLA mutant frequencies have not been determined in XP patients. For Bloom syndrome, both gpa and hprt variant frequencies were increased, with no mutagenicity studies reported for the other assays (37, 38) . Unlike in AT, however, both hemizygous and homozygous gpa variant frequencies were increased in Bloom syndrome, perhaps reflecting the marked chromosome level changes seen in the disorder. A single study has reported increased hprt variant and mutant frequencies in some patients with Fanconi anemia and another an increase in hprt variant frequency in individuals with Werner syndrome (39, 40) . In all of the DNA repair deficiency conditions tested, the constitutional heterozygotes had, on average, normal background variant/mutant frequency values.
Induced Variant/Mutant Frequencies
Several studies have investigated the effects of exposures to genotoxic agents in adult humans. These include ionizing irradiations (Table 2 ) and several chemical agents (Table 3) .
Exposure to external beam ionizing irradiation results in increases in hprt mutant frequencies in both radiotherapy technicians and patients, but not in increases in gpa variant frequencies (32, 33, (41) (42) (43) (44) . Atomic bomb survivors studied 45 years after exposure showed increases in both hprt mutant and gpa variant frequencies (15, (45) (46) (47) . Both showed a dose-response relationship with exposure level and the slope was higher for the gpa response. This latter difference may reflect the different sites of mutations in RBCs and T-lymphocytes, and the potential long life of RBC stem-cell mutants. However, the increased frequency of hprt mutants also demonstrates the long life of some mutant T-cells in vivo. An increase in the frequency of Hb, gpa, and hprt variants has been reported in individuals exposed to radiation as a result of accidental environmental contamination (6, 24, (48) (49) (50) .
Internal exposure to technetium-99m through radionuclide angiography has yielded conflicting results in studies of hprt mutant frequency (51, 52) . However, internal exposure to yttrium-90 or iodine-131 through a radioimmunotherapy (RIT) procedure clearly resulted in increases in the hprt mutant frequency, which correlated with the initial doses of administered radioactivity (53, 54) . (A specific spectrum of mutations was also found, as described below.) Lastly, household exposure to radon has been shown to yield a correlation between increased hprt mutant frequency and total exposure (55) .
Exposure to chemical agents such as those in combination chemotherapy results in an increased frequency of gpa variants and hprt mutants (56) (57) (58) ). An increase in hprt variant frequency was found in two studies of the effects of exposure to cyclophosphamide, either therapeutic or occupational (23, 59) . Occupational exposure to ethylene oxide resulted in increases in both the Hb variant and hprt mutant frequency (60, 61) .
When the studies were able to access the longitudinal stability of the increased variant/mutant frequencies, elevations were generally found to be transient over time. Thus, the assays appear to be able to detect recent exposures to genotoxic agents. However, the effects of exposures in the more distant past to ionizing irradiation are also clearly demonstrated. Chronic exposures, as in the radon study, may be most relevant for human risk assessment, and more studies of this type are needed.
Molecular Analyses of in Vivo Somatic Mutations in Humans
Hprt and HLA mutations arising in vivo in T-lymphocytes may be analyzed at the molecular level using techniques such as direct Southern blotting or genomic polymerase chain reaction (PCR) amplification to define major structural alterations and the direct PCR of cDNA and sequencing to characterize point mutations (62) (63) (64) . In adition, studies of TcR gene rearrangement patterns among mutants from a given individual establish clonal distributions of in vivo-derived mutants (65) .
Background Mutations
Approximately 15% of the background in vivo hprt mutations in adults show gross structural alterations visible on Southern blots. Most of these alterations are deletions. Only the minority, however, are total (i.e., involving all nine exons of hprt). Breakpoints are apparently randomly distributed throughout the gene with no hot-spots thus far identified.
The remaining 85% of background in vivo hprt mutations in adults are due to point mutations, i.e., base changes, frameshifts, splice-site alterations, or small deletions or insertions, involving less that the 500 El) necessary for detection on Southem blots. A repository is being maintained by Thomas Skopek at the University of North Carolina at Chapel Hill to collate all data on such hprt point mutations. This repository now includes information concerning both spontaneous (background) and induced in vivo and in vitro mutations in human cells. Overall, the most common point mutations observed at hprt are base substitutions (85% missense, 13% nonsense, 2% no amino acid change), followed by splice site mutations, frameshifts, and small deletions. Every class ofbase substitution has been observed at similar frequencies, and these have been distributed throughout all nine exons. Splice site mutations have involved all exons except exon 1. Frameshift mutations, in general, occur at or adjacent to sequences containing two or more consecutive identical bases, whereas small deletions, involving from 2 to 49 bp, are often flanked by 2-5 base direct repeat sequences.
The background in vivo hprt T-cell point mutations have thus far not shown a characteristic pattern or spectrum. However, several hot-spots have been observed, i.e., sites at which mutation has occurred more than once. Given the large target size of hprt, the current inability to define a spontaneous mutational spectrum is not unexpected; the total number of background in vivo hprt mutations analyzed to date has simply not been sufficient.
Unexpectedly, the background hprt mutational spectrum of newborn humans, determined from T-cell mutants isolated from placental blood and reflecting mutations in the fetus, is quite different from that determined for adults. Rather than 15% showing gross structural alterations on Southern blots, up to 85% of fetal mutations show such gross changes (66, 67) . Furthermore, while adult breakpoints for gross alterations are randomly distributed within the hprt gene, fetal mutations have a characteristic partial deletion that involves only exons 2-3. These mutations have been shown to contain specific breakpoints in introns 1 and 3, which is consistent with the known specificity of the VDJ recombinase activity (68) . Molecular analyses of in vivo HLA T-cell mutations are also in progress. Southern blot studies of background mutants from nonexposed adults reveal that approximately 30% result from total gene deletions. Significantly, the use of chromosome 6p polymorphic DNA probes further shows another 30% to be homozygous for markers for which the individual is constitutionally heterozygous. The most likely interpretation is that these in vivo background HLA mutations result from a process akin to somatic recombination (69, 70) . If so, HLA becomes an important recorder for such events. At present, molecular studies of in vivo HLA mutations are being pursued by a single group. There are no published molecular characterizations of in vivo fetal mutations, or of the remaining 30 + % of in vivo background mutations in adults that appear to be point mutations.
Induced Mutations
The only molecular mutational spectrum thus far defined for induced in vivo somatic mutations in humans is for hprt in individuals following exposures to ionizing radiation (53, 54) . The exposed individuals are cancer patients receiving radioimmunoglobulin therapy (RIT). RIT involves the intravenous administration of a radionuclide linked to an antibody that localizes to tumor and other body tissues, thus providing chronic total body irradiation in an exponentially decaying dose. Two hundred forty-one independent in vivo hprt mutational events occurring in 19 RIT patients, 118 independent in vivo hprt mutations in four cancer patients before RIT, and 287 background mutations in normal individuals were analyzed by Southern blots and the results compared. The mean percent of gross structural alteration mutations in the radiation-exposed group was 38.3%, compared to 16.9% in cancer patients before RIT and 14.2% in normal adults. Thus, ionizing radiation resulted in a characteristic in vivo hprt molecular mutational spectrum characterized by deletions. The spectral change from background is not produced by the cancer itself, as it does not occur in cancer patients pre-RIT. Further analysis showed the average size of hprt deletions to be increased by ionizing radiation. Forty-one percent of the gross structural alterations in the radiation associated mutations were total hprt deletions, compared to 22% and 15% in normal adults and pre-RIT cancer patients, respectively. Molecular studies using linked X-chromosome DNA anonymous probes and pulsed-field gel electrophoresis have shown that some of the hprt deletions are quite large, i.e., up to 2 Mb (71,72). Finally, a correlation was found between the percentage of in vivo hprt mutations in an individual showing a gross structural alteration and the cumulative radiation dose received by the individual. In fact, 67% of this variability could be explained by the ionizing radiation exposure. This study indicates that determining the in vivo hprt molecular mutational spectrum is valuable in individuals exposed to ionizing radiation, and may be as important as quantitative mutation studies for this particular genotoxic risk recognition.
Conclusions
Genetic damage manifest as gene mutations can clearly be determined in human somatic cells and the mutagenic effects of exposure to genotoxic agents can be quantified.
The four assays described here provide the ability to detect a complete spectrum of mutagenic effects. The RBC assays have the potential advantage of long memory because of the stem-cell component. The T-lymphocyte assays allow direct molecular characterization of the full range of mutation events and the advantage of providing a temporal relationship between the exposure and the mutation event.
These biomarkers can clearly provide measurement of somatic cell mutations occurring in human and the increases which result from exposure to genotoxic agents. Future studies will determine the correlation of these specific somatic cell effects with human genotoxic diseases and the utility of these assays for risk assessment.
